# Supernus Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Supernus Pharmaceuticals, Inc). ## Overview Supernus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its portfolio includes approved and marketed therapies for ADHD, Parkinson’s disease-related movement disorders, epilepsy, migraine, postpartum depression, cervical dystonia, and chronic sialorrhea, along with a pipeline of CNS product candidates. ## Products & services • Commercial CNS medicines for ADHD and neurology • Parkinson’s disease therapies and movement-disorder treatments • Specialty products for migraine, dystonia, and sialorrhea • Postpartum depression therapy through collaboration revenue • CNS drug development and clinical-stage product candidates - **Commercial neuroscience products** (80%) — Approved and marketed medicines for ADHD, Parkinson’s disease, epilepsy, migraine, dystonia, and sialorrhea. - **Specialty pharmacy products** (15%) — Products distributed mainly through specialty pharmacies, including therapies for movement disorders and postpartum depression. - **Collaboration revenue** (3%) — Revenue from partnered products such as ZURZUVAE under commercialization or profit-sharing arrangements. - **Pipeline and development programs** (2%) — Clinical-stage CNS candidates such as SPN-817, SPN-820, and SPN-443. - Commercial CNS medicines for ADHD and neurology - Parkinson’s disease therapies and movement-disorder treatments - Specialty products for migraine, dystonia, and sialorrhea - Postpartum depression therapy through collaboration revenue - CNS drug development and clinical-stage product candidates ## Customers Supernus sells primarily to pharmaceutical wholesalers, specialty pharmacies, and distributors, which then supply pharmacies, hospitals, and other healthcare customers. Some products are also purchased directly by physicians and hospitals, while certain therapies are distributed through specialty pharmacy channels because of patient support, access, and handling requirements. - **Pharmaceutical wholesalers** (primary) — Buy the majority of product sales for several brands and distribute into the broader pharmacy channel. - **Specialty pharmacies** (primary) — Buy and dispense therapies such as GOCOVRI, APOKYN, ONAPGO, and ZURZUVAE where patient support matters. - **Distributors** (primary) — Handle product flow for brands sold through channel partners, especially in broad commercial access markets. - **Physicians and hospitals** (secondary) — Purchase certain products directly, including MYOBLOC, for in-office or institutional use. - **Government and public payors** (secondary) — Indirectly consume products through downstream channels and influence access, rebates, and reimbursement. - Pharmaceutical wholesalers that resell to pharmacies and institutions - Specialty pharmacies for complex CNS and specialty therapies - Distributors serving retail, hospital, and government channels - Physicians and hospitals for direct-purchase products like MYOBLOC - Federal and state entities reached through downstream distribution ## Geography Supernus is headquartered in Rockville, Maryland and operates as a U.S.-based company with commercial activity centered in the United States. The business is exposed to U.S. reimbursement, FDA regulation, and domestic channel concentration, while some supply and vendor relationships extend outside the United States. - Headquartered in Rockville, Maryland, United States - Commercial sales are primarily in the U.S. market - U.S. reimbursement and FDA oversight shape access and launch timing - Some suppliers and clinical manufacturing vendors are outside the U.S. - Domestic channel concentration increases exposure to U.S. payor dynamics ## Strategy Supernus is focused on expanding its neuroscience franchise through commercial execution in ADHD and movement disorders while advancing a pipeline of CNS candidates. The company also uses business development and acquisitions to add marketed assets and broaden its portfolio, as shown by its Sage Therapeutics transaction and the addition of ZURZUVAE. - **Expand commercial CNS franchise** (short-term) — The company depends on branded product sales, so growth in core franchises supports scale and portfolio durability. - **Advance pipeline candidates** (medium-term) — Clinical programs create future product opportunities and reduce reliance on older brands. - **Add assets through business development** (medium-term) — Acquisitions and collaborations can quickly expand the commercial portfolio and pipeline. - **Replace products facing exclusivity loss** (short-term) — Patent expirations can erode legacy revenue, so portfolio renewal is important for continuity. - Grow core ADHD and neurology brands through commercial execution - Support new product launches such as ONAPGO - Advance clinical programs in epilepsy, depression, and ADHD - Use acquisitions and collaborations to broaden the CNS portfolio - Manage patent expirations by replacing mature products with new assets ## Risks Supernus faces concentration in a few commercial products and channel partners, making revenue sensitive to prescription trends, reimbursement, and wholesaler purchasing patterns. The company also faces regulatory, patent, supply-chain, and acquisition-related risks that are common in specialty pharmaceuticals and can affect launches, margins, and asset values. - **Customer concentration** [high] — Three wholesalers accounted for more than 15% each of product revenue, creating dependence on a few channel partners. - **Patent and exclusivity loss** [high] — Loss of exclusivity on legacy products can sharply reduce revenue as generic competition enters. - **Regulatory and reimbursement pressure** [high] — FDA requirements and payor coverage decisions can affect approval timing, pricing, and patient access. - **Supply chain and vendor dependence** [medium] — The company relies on third-party manufacturers and suppliers, including non-U.S. vendors, for active ingredients and drug substances. - **Integration and valuation risk from acquisitions** [medium] — Business combinations require purchase accounting judgments and can create goodwill or intangible asset impairment exposure. - Revenue depends on a small number of branded CNS products - Wholesaler and specialty pharmacy concentration increases channel risk - Patent and exclusivity loss can reduce sales of mature products - FDA and reimbursement changes can delay launches or limit access - Supply constraints and third-party vendors can disrupt product availability ## Accounting Supernus’ most important accounting judgments center on net product revenue, which is recognized after control transfers and net of rebates, discounts, and returns. The company also has material estimates around acquired intangible assets, contingent consideration, and impairment testing, all of which can materially affect reported earnings after acquisitions or product changes. - **Revenue deductions and returns** — Quarterly revenue and gross-to-net adjustments - **Medicaid rebate accruals** — Earnings volatility and reserve true-ups - **Business combination accounting** — Purchase accounting, amortization, and future impairment risk - **Impairment of definite-lived intangibles** — Non-cash charges to operating results - Net product revenue depends on rebate, discount, and return estimates - Medicaid rebate timing can cause quarter-to-quarter accrual swings - Acquired assets and goodwill require valuation judgments in business combinations - Contingent consideration must be remeasured using probability assumptions - Definite-lived intangible assets may require impairment if product value weakens --- *Last updated: 2026-09-24T11:32:27.935256+00:00*